Submit Manuscript  

Article Details


Pre-operative Exposure to Ustekinumab: A Risk Factor for Postoperative Complications in Crohn's Disease (CD)?

[ Vol. 20 , Issue. 13 ]

Author(s):

Hang Hock Shim*, Christopher Ma, Paulo Gustavo Kotze and Remo Panaccione   Pages 1369 - 1372 ( 4 )

Abstract:


Crohn’s disease (CD) is a chronic inflammatory condition of the intestinal tract that is characterised by a relapsing and remitting course. Despite advancements in therapeutic options for CD, a substantial number of patients still require surgery for medically refractory disease or disease-related complications. Given the widespread adoption of biologic therapies for the management of patients with moderate-to-severe CD, a high number of patients are likely to be on biologic therapy at the time of needing intestinal surgery: the safety of biologics in perioperative setting is of great interest. While more clinical data are available for TNF antagonists and vedolizumab, the safety data for ustekinumab, an IL 12/23 inhibitor, is lacking. Here, we review the available data from published literature on the postoperative outcomes for CD patients exposed to ustekinumab perioperatively.

Keywords:

Ustekinumab, Crohn's disease, surgery, chronic inflammatory, biologic therapies, vedolizumab.

Affiliation:

Department of Gastroenterology and Hepatology, Singapore General Hospital, Inflammatory Bowel Disease Unit, Division of Gastroenterology and Hepatology, University of Calgary, Calgary, Inflammatory Bowel Disease Unit, Division of Gastroenterology and Hepatology, University of Calgary, Calgary, Inflammatory Bowel Disease Unit, Division of Gastroenterology and Hepatology, University of Calgary, Calgary



Read Full-Text article